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Efficacy of Ultrasound-guided 
Radiofrequency Ablation of 
Parathyroid Hyperplasia: Single 
Session vs. Two-Session for Effect 
on Hypocalcemia
Zeng Zeng1, Cheng-Zhong peng1*, Ji-Bin Liu2, Yi-Wen Li3, Hong-Feng He1, Qiao-Hong Hu1, 
Bo Lin3 & Xiao-Gang Shen3
To evaluate safety and efficacy of one- vs. two-session radiofrequency ablation (RFA) of parathyroid 
hyperplasia for patients with secondary hyperparathyroidism (SHPT) and to compare the outcome 
of both methods on hypocalcemia. Patients with secondary hyperparathyroidism underwent 
ultrasound guided RFA of parathyroid hyperplasia. Patients were alternately assigned to either 
group 1 (n = 28) with RFA of all 4 glands in one session or group 2 (n = 28) with RFA of 2 glands in a 
first session and other 2 glands in a second session. Serum parathyroid hormone (PTH), calcium, 
phosphorus and alkaline phosphatase (ALP) values were measured at a series of time points after RFA. 
RFA parameters, including operation duration and ablation time and hospitalization length and cost, 
were compared between the two groups. Mean PTH decreased in group 1 from 1865.18 ± 828.93 pg/
ml to 145.72 ± 119.27 pg/ml at 1 day after RFA and in group 2 from 2256.64 ± 1021.72 pg/ml to 
1388.13 ± 890.15 pg/ml at 1 day after first RFA and to 137.26 ± 107.12 pg/ml at 1 day after second RFA. 
Group 1’s calcium level decreased to 1.79 ± 0.31 mmol/L at day 1 after RFA and group 2 decreased to 
1.89 ± 0.26 mmol/L at day 1 after second session RFA (P < 0.05). Multivariate analysis showed that 
hypocalcemia was related to serum ALP. Patients with ALP ≥ 566 U/L had lower calcium compared to 
patients with ALP < 566 U/L up to a month after RFA (P < 0.05). Group 1’s RFA time and hospitalization 
were shorter and had lower cost compared with Group 2. US-guided RFA of parathyroid hyperplasia is 
a safe and effective method for treating secondary hyperparathyroidism. Single-session RFA was more 
cost-effective and resulted in a shorter hospital stay compared to two sessions. However, patients with 
two-session RFA had less hypocalcemia, especially those with high ALP.
Secondary hyperparathyroidism (SHPT) commonly occurs in patients with end stage renal disease (ESRD) when 
low calcium levels and high phosphorus levels over time stimulate increased PTH secretion1–3. SHPT increases 
the risk for osteoporosis and kidney stones, as well as for parathyroid hyperplasia, a condition that can cause 
mental abnormalities, renal osteodystrophy, calcific uremic arteriolopathy, vascular calcification, muscle spasms 
and even lead to respiratory or cardiac arrest4.
Treatment for SHPT includes vitamin D sterols, intravenous vitamin D analogs and cinacalcet5–10 to improve 
biochemical profiles and other surrogate markers11. Patients with severe SHPT may be candidates for parath-
yroidectomy (PTX), which increases long-term survival and reduces the risk of fracture in ESRD patients12. 
However, hyperparathyroidism recurs in up to 30% of patients treated with PTX due to incomplete excision of all 
hyperplasic parathyroid glands13,14. Meanwhile, PTX can potentially result in permanent hypoparathyroidism if 
the parathyroid glands are over-excised15.
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Recently, various percutaneous ablation methods have been used in treating patients with hyperparathy-
roidism, including ethanol injection16, acetic acid injection17, laser ablation18, high-intensity focused ultrasound 
(HIFU) treatment19, microwave ablation20–22 and radiofrequency ablation (RFA)23–25. Ethanol injection is consid-
ered a minimally invasive treatment for SHPT, but the 1-y recurrence rate is 80% due to incomplete ablation26. 
Laser ablation use in parathyroid gland diseases has mainly focused on primary hyperparathyroidism caused by 
parathyroid gland adenoma27–29. Meanwhile HIFU is not yet a clinically viable option because the equipment 
needed is not widely available. Both microwave ablation and RFA are considered minimally invasive techniques 
with similar a principle and mechanism for local tissue coagulation. We have used RFA to treat parathyroid 
hyperplasia in patients with SHPT and to reduce serum PTH, calcium, and phosphorus levels. Complications 
from RFA, such as nerve injury, hemorrhage, infection, trauma and fever, are fewer and recovery is shorter com-
pared with surgery30.
RFA has been shown to be particularly feasible for optimally treating SHPT patients with chronic kidney 
disease (CKD) whose PTH level is > 800 pg/mL31. In these patients, both under- and over-treatment can result 
in serious complications. In SHPT overtreatment, parathyroid gland inhibition can lead to low PTH levels and 
cause dynamic bone disease and even increased mortality. However, SHPT undertreatment can allow high PTH 
levels to induce a series of systemic disorders related to abnormal mineral metabolism of the bone, which seri-
ously affects quality of life and can be life threatening. Thus, serum PTH levels must be maintained at a reasonable 
level for patients with CKD on dialysis32–34. For patients with ESRD, intact PTH levels should be 150–300 pg/
mL, according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative35. Because of 
variability in PTH measurement, the 2009 Kidney Disease Improving Global Outcomes (KDIGO) guidelines 
suggested that patients with CKD-Stage 5D should control their PTH levels between 2- and 9-fold of the upper 
limit of normal2.
Our previous studies demonstrated that ultrasound (US)-guided RFA of parathyroid hyperplasia is effective 
for treating SHPT30. However, the severe hypocalcemia has been critical issues after thermal ablation, which may 
be related to the timing and sessions of the treatment. Many complications will occur if in severe hypocalce-
mia, such as neuromuscular irritability, seizures, myocardial dysfunction and pulmonary abnormalities36. Recent 
research hypotheses that because of trasnsient severe hypocalcemia, the mortality rate would be higher37. Thus, 
maintaining calcium in a normal level becomes very important. Few studies showed that the preoperative alkaline 
phosphatase (ALP) level and the PTH level could be used to predict the calcium level after treatment as well as the 
RFA modes38. The purpose of current study was to evaluate the safety and efficacy of one-session vs. two-session 
RFA of parathyroid hyperplasia in patients with SHPT and to compare the effect and outcome of both methods 
on hypocalcemia.
Materials and Methods
Patients. This study was approved by the ethical and scientific review board of Zhejiang Provincial People’s 
Hospital. Written informed consent was obtained from all patients enrolled in this study. We confirm that all 
methods were performed in accordance with the relevant guidelines and regulations. From January 2015 to June 
2018, we retrospectively studied 56 patients (22 men, 34 women) who were diagnosed as secondary hyperparath-
yroidism caused by CKD. All 56 patients had dialysis history, including 21 patients with the peritoneal method 
and 35 patients with hemodialysis. The inclusion criteria were: (1) PTH ≥ 800 ng/ml; (2) 4 hyperplastic para-
thyroid glands found by ultrasound (Fig. 1); (3) uncontrollable SHPT using medication treatment; and (4) no 
severe bleeding disorders, cardiac insufficiency, or uncontrollable hypertension. The exclusion criteria were: (1) 
abnormal vocal cord movement by laryngoscopy; (2) abnormal coagulation function tests (prothrombin time > 
25 seconds, prothrombin activity < 40% and platelet count <100 × 109/L); (3) refusing RFA by patient; (4) severe 
cardiopulmonary dysfunction; and (5) When hoarseness occur after the first session ablation.
Patients were alternately assigned into 2 groups: group 1 (n = 28) with RFA of all 4 glands in one session and 
group 2 (n = 28) with RFA of 2 glands in a first session and 2 glands in a second session 1 week later.
Laboratory tests and follow-up. All patients’ demography, primary disease, dialysis history, and clinical 
symptoms were recorded. Blood tests of PTH, calcium, and phosphorus were conducted 24 hours before RFA, 
and on day 1, day 3, 1 week, and 1 month after RFA. Normal ranges were defined as: PTH 11–62 pg/mL, serum 
calcium 2.11–2.52 mmol/L and serum phosphorous 0.85–1.51 mmol/L. Clinically, serum calcium <1.8 mmol/L 
is considered as obviously low calcium, warranting treatment with intravenous calcium supplementation. Thus, 
blood calcium <1.8 mmol/L was used as the standard for remarkable low calcium limitation. When blood cal-
cium is lower than 2 mmol/L but higher than 1.8 mmol/L, oral calcium supplementation is given and otherwise, 
intravenous calcium will be administered. Previous studies showed that after parathyroidectomy bone resorp-
tion markers decreased significantly after 24 hours while bone formation markers changed minimally39,40. In this 
study, the lowest calcium level on the first day after RFA was used to decide whether hypocalcemia or not in order 
to avoid the effect of active calcium supplementation given later. Because alkaline phosphatase (ALP) is a marker 
for bone formation and could not change noticeably within 1 to 3 days after RFA, measurement of bone ALP was 
performed before RFA and at 1 week and 1 month after RFA.
US-Guided RFA. RFA procedure was performed by single doctor (CZP) with 22 years of experience in inter-
ventional ultrasound and 10 years of experience in RFA treatment of thyroid and parathyroid nodules. Patients 
were placed in a supine position with their necks elevated using a pillow under their shoulders. With routine 
disinfection and draping as well as 2% lidocaine local anesthesia, US-guided RFA was performed using grey-scale 
imaging with a iU22 US scanner and a high-frequency linear probe (L12-5) (Philips, The Netherlands) while 
contrast-enhanced ultrasound (CEUS) with a high-frequency linear probe (L9-3) was used to monitor the RAF 
procedures (Fig. 2). Thermal ablation of hyperplastic parathyroid glands was conducted using a radiofrequency 
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generator with an 18-gauge monopolar internally cooled electrode (VIVA; STARmed, Goyang, Korea). The radi-
ofrequency electrode had a 7-cm length shaft with a 0.7-cm active tip and was cooled by a water circulation pump 
(VIVA pump; STARmed).
In order to avoid thermal injury of adjacent structures, a buffering zone was created by injection of 10–30 mL 
of 0.9% sterile saline solution around the hyperplastic parathyroid to establish a liquid isolation zone>1 cm 
in depth between the parathyroid and adjacent structures (Fig. 3). Then, the RFA electrode was inserted and 
deployed 1 mm away from the back of the parathyroid gland under real-time US guidance. Thermal ablation 
effect showed a hyperechoic area within the coagulated tissue. The entire targeted glands were ablated by moving 
the electrode step-by-step until coagulation was complete. During the procedure and after ablation of each gland, 
the operator attempted to ask the patients to evaluate their voice. If voice hoarseness happened, the procedure was 
stopped. If not, the procedure continued.
Statistical analysis. Data analysis was performed using the SPSS software (SPSS for Windows 22.0, SPSS, 
Chicago, IL) and Graphpad Prism version 4.03 (California, USA). Continuous variables were expressed as the 
mean ± standard deviation. Multivariate logistical regression analysis was used to screen independent features 
Figure 1. Ultrasound found 4 hyperplastic parathyroid nodules in a patient with secondary 
hyperparathyroidism (SHPT) and confirmed by ECT. (a) The middle and lower right parathyroid gland (yellow 
arrow). (b) The lower right parathyroid gland (black arrow). (c) The upper left parathyroid gland (blue arrow). 
(d) The lower left parathyroid gland (purple arrow). (e) Emission computed tomography (ECT) coronal image 
shows that nodule has concentration of radioactivity in the initial phase (20 min) and late phase (120 min) of 
99 m Tc-sestamibi sequence.
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for the occurrence of low calcium. Continuous variables were analyzed by using the Student t test. P < 0.05 was 
used to define significance.
Results
Patient demographics and clinical features of appear in Table 1. For group 1 patients, the maximum diame-
ter of the glands ranged from 0.7 cm to 2.9 cm (mean, 1.4 cm ± 0.5). For group 2 patients, the maximum 
diameter of the glands ranged from 0.8 cm to 2.5 cm (mean, 1.6 cm ±0.4). Table 2 shows the results of the labo-
ratory test analysis. In group 1, mean PTH level decreased from 1865.18 ± 828.93 pg/ml to 145.72 ± 119.27 pg/
ml at 1 day after RFA and to 289.04 ± 197.99 pg/ml at 1 month after RFA. In group 2, mean PTH level 
Figure 2. (a) The radiofrequency ablation (RFA) electrode reached the location on the back of the parathyroid 
gland. (b) Contrast enhanced ultrasound (CEUS) was used to monitor the radiofrequency ablation (RFA) 
procedures, a buffering zone (green dotted line) around the hyperplastic parathyroid (red dotted line).
Figure 3. We injected 15 ml 0.9% sterile saline solution to create a buffering zone (green dotted line) around the 
hyperplastic parathyroid (red dotted line) in order to establish a liquid isolation zone >1 cm in depth between 
the parathyroid and adjacent structures.
Features
Group 1 
(N = 28)
Group 2 
(N = 28)
Sex
Male 7 15
Female 21 13
Age 53.50 ± 10.06 45.53 ± 12.93
Dialysis Method
Peritoneal 11 10
Hemodialysis 17 18
Dialysis Duration(months) 93.00 ± 28.67 90.66 ± 26.98
Table 1. Clinical features of group 1 and group 2 patients with SHPT.
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decreased from 2256.64 ± 1021.72 pg/ml to 1388.13 ± 890.15 pg/ml at 1 day after first-session RFA and then 
rebounded to 1625.92 ± 1129.43 pg/ml at 7 days later. Group 2 mean PTH decreased sharply and rapidly from 
1677.66 ± 1012.36 pg/ml to 137.26 ± 107.12 pg/ml at 1 day after second-session and to 230.92 ± 190.23 pg/ml at 
1 month after second-session RFA. The mean PTH level in group 1 and group 2 after complete RFA was not sta-
tistically significant (P > 0.05).
Calcium decreased quickly after RFA both in group 1 and group 2 patients (Fig. 4). 27 patients (27/28, 96.4%) 
in Group 1 had hypocalcemia on the 1st day after RFA. In Group 2, 24 patients (24/28, 85.7%) had hypocalcemia 
on the 1st day after second session of RFA. The calcium line of group 1 was below group 2. The mean calcium 
level in group 1 decreased quickly from 2.59 ± 0.17 mmol/L before RFA to 1.79 ± 0.31 mmol/L at day 1 after RFA. 
The mean calcium level in group 2 also decreased from 2.53 ± 0.19 mmol/L before RFA to 2.22 ± 0.23 mmol/L at 
day 1 after first-session RFA and to 1.89 ± 0.26 mmol/L at day 1 after second-session RFA. Calcium level between 
group 2 after second RFA and group 1 at day 1 had significance (P <0.05). In group 1, 17 patients had oral calcium 
supplementation, 10 patients had intravenous calcium administration and 1 patients had no need to have calcium 
supplement. In group 2 after 2nd RFA, 14 patients had oral calcium supplementation, 10 patients had intravenous 
calcium administration and 4 patients had no need to have calcium supplement. After active calcium supplemen-
tation therapy, calcium levels gradually increased.
Table 3 shows the binary logistic regression analysis of PTH and ALP values (before RFA) for occurrence 
of hypocalcemia. Although both serum PTH and ALP presented as significant factors for the occurrence of 
hypocalcemia, ALP’s effects on hypocalcemia occurrence was significant (P < 0.05) compared to PTH’s effects 
(P > 0.05). When the cutoff point of ALP level was set as 566 U/L, an area under the ROC curve was 0.965, 
Youden index of 0.896, sensitivity of 95.0% and specificity of 94.6% (Fig. 5).
When we separated patients into a high ALP group (≥566 U/L; 20 patients) and low ALP group (<566 U/L; 
36 patients) and measured calcium levels, we found that mean calcium levels at day 1, day 3, 1 week and 1 month 
after RFA were lower in the high ALP group than in the low ALP group (P < 0.05) (Table 4). Figures 6 and 
7 showed the calcium level of group 1 and group 2 patients with different ALP levels. For both two groups, 
ALP ≥ 566 U/L patients’ calcium level were lower than patients whose ALP < 566 U/L. For the high ALP group, 
Laboratory tests
Group 1 Group 2(1st RFA) Group 2(2nd RFA)
Before RFA After RFA(day 1) Before RFA After RFA(day 1) Before RFA After RFA(day 1)
PTH, pg/ml 1865.18 ± 828.93 145.72 ± 119.27 2256.64 ± 1021.72 1388.13 ± 890.15 1677.66 ± 1012.36 137.26 ± 107.12
Calcium, mmol/L 2.59 ± 0.17 1.79 ± 0.31 2.53 ± 0.19 2.22 ± 0.23* 2.31 ± 0.19 1.89 ± 0.26*
Phosphorus, mmol/L 2.08 ± 0.32 1.57 ± 0.44 2.10 ± 0.58 1.89 ± 0.57 1.70 ± 0.32 1.28 ± 0.56
ALP, U/L 488.03 ± 439.80 488.04 ± 447.87 612.89 ± 550.13 590.46 ± 556.55 662.39 ± 527.13 690.47 ± 528.03
Table 2. Laboratory tests of group 1 and group 2 patients before and after RFA. P*<0.05 for group 2 compared 
with group 1 after first RFA on day 1. Normal ranges: PTH 11–62 pg/mL, Calcium 2.11–2.52 mmol/L and 
Phosphorous 0.85–1.51 mmol/L.
Figure 4. Calcium level of Group 1 and Group 2 patients after RFA.
β SE Wald P OR (95%CI)
Constant −2.728 2.303 9.351 0.002
PTH 0.000 0.001 0.823 0.364 1.000(0.999–1.001)
ALP 0.003 0.001 5.316 0.021* 1.003(1.001–1.006)
Table 3. Binary logistic regression analysis of PTH and ALP values (before RFA) for occurrence of 
hypocalcemia.
6Scientific RepoRtS |         (2020) 10:6206  | https://doi.org/10.1038/s41598-020-63299-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
patients with single-session RFA had lower calcium (1.45 ± 0.25 mmol/L) compared to patients with two session 
RFA 1 day after RFA (1.68 ± 0.17 mmol/L) (P < 0.05). For the low ALP group, patients with single- or two-session 
RFA had similar low calcium levels (1.98 ± 0.10 mmol/L vs. 2.00 ± 0.27 mmol/L respectively, P > 0.05).
We also found differences in procedure cost, RFA time, total operation time, and hospitalization time for 
group 1 and group 2 patients (Table 5). Compared to group 1, costs for the patients in group 2 were higher 
($2484.39 ± 199.68 vs. $4658.16 ± 349.37 respectively, P < 0.05) and hospitalization was longer (8.32d ± 1.61 
and 15.93d ± 1.60, respectively, P < 0.05). Mean operation duration was 90.53 min±10.31 for group 1 
and 100.74 min±8.9 for group 2 of two sessions. The mean RFA time was 225.85 sec±41.85 for group 1 and 
214.52 sec±20.47 group 2 for two sessions.
All patients tolerated the procedures with no major complications. All patients had mild swallowing and 
variable pain after RFA that disappeared gradually in a few days. One patient in the two-session ablation group 
developed vocal hoarseness after second ablation and recovered within 70 days.
Discussion
In previous study, Zhou et al. demonstrated the feasibility and efficacy of microwave ablation of parathyroid 
glands and showed that serum PTH and calcium decreased significantly after MWA in patients with SHPT41. In 
current study, we used US-guided RFA to treat parathyroid hyperplasia in 56 patients with SHPT caused by CKD. 
Our study showed PTH decreased significantly after RFA for patients in both the one-session and two-session 
groups. These decreased PTH levels remained decreased and within accepted Kidney Disease Improving Global 
Outcomes limits2 in most of the patients (52/56) at 1 month after RFA, which indicated that RFA can inactivate 
hyperplastic parathyroid glands and achieved the desired therapeutic effect.
Hypocalcemia is the most common complication after parathyroid resection surgery. In addition to symp-
toms such as limb numbness and cramps, hypocalcemia can also cause severe complications such as bronchos-
pasm, gastrointestinal spasm, and arrhythmia. Therefore, close postoperative monitoring of blood calcium and 
timely treatment are critical and necessary. In general, blood calcium should be monitored 2–4 times a day after 
surgery. When blood calcium is lower than 2.11 mmol/L but higher than 1.8 mmol/L, oral calcium supplemen-
tation is given; when blood calcium is lower than 1.8 mmol/L, intravenous calcium supplementation is given. 
Hypocalcemia is also a common complication of thermal ablation. Our study shows hypocalcemia occurred on 
Figure 5. ROC curve of alkaline phosphatase (ALP) shows area under the curve of 0.965, sensitivity of 95.0% 
and specificity of 94.6% using alkaline phosphatase (ALP) cutoff point as 566 mmol/L.
Calcium, mmol/L
Low ALP group 
(N = 36)
High ALP group 
(N = 20) P Value
Before RFA 2.40 ± 0.20 2.38 ± 0.22 0.120
Day 1 after RFA 2.03 ± 0.36 1.56 ± 0.24 0.000
Day 3 after RFA 2.12 ± 0.40 1.66 ± 0.15 0.000
1 week after RFA 1.98 ± 0.17 1.80 ± 0.11 0.000
1 month after RFA 2.16 ± 0.19 1.94 ± 0.13 0.040
Table 4. Mean calcium values before and after RFA in high ALP (>566 U/L) and low ALP (<566 U/L) patients.
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the first day after RFA. When hypocalcemia occurred after RFA, active calcium supplementation therapy was 
effective to gradually correct the calcium level.
PTH has many target organs such as bones, kidneys and the intestinal tract. Because PTH can bind to its 
receptors on osteoclasts and stimulates bone resorption, it leads to the release of calcium into the blood42. In fact, 
even small changes of serum ionized calcium (lower than 0.1 mmol/L) can cause obvious changes in PTH43,44. The 
Figure 6. Calcium level of ALP ≥ 566 mmol/L patients and ALP < 566 mmol/L patients in Group 1 after RFA.
Figure 7. Calcium level of ALP ≥ 566 mmol/L patients and ALP <566 mmol/L patients in Group 2 after RFA.
Group 1 Group 2 P Value
Hospital stay 8.32d ± 1.61 15.93d ± 1.60 0.000
Cost of RFA 2484.39$ ± 199.68 4658.16$ ± 349.37 0.000
Ablation time 225.85 sec ± 41.85 214.52 sec ± 20.47 (two sessions)
Operation duration 90.53 min ± 10.31 100.74 min ± 8.9 (two sessions)
Table 5. Hospital stay, cost of RFA, ablation time, and operation duration in group 1 and 2 patients.
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effect of low level PTH on bone is mainly osteogenesis and the effect of high level PTH on bone is both osteogen-
esis and osteoclast. High PTH has greater effects on osteoclast than osteogenesis20,45. Thus, patients with SHPT 
have high serum PTH and high metabolism of bone transport30. With complete ablation of hyperplastic parathy-
roids, serum PTH can decrease rapidly alone with osteoclast activity decreased or disappeared in a short time, 
and then osteoblastic activity continues. Therefore, in order to keep normal bone metabolism, the components of 
calcium and phosphorus in the blood must reach the level that the process of bone formation can lead to a rapid 
decrease of serum calcium and phosphorus levels in a short period of time, a process known as bone starvation46. 
Hypocalcemia after parathyroid RFA or surgery is related to bone starvation.
ALP is an indicator of osteogenesis to some extent, it reflects the high transport state of bone metabolism. 
Therefore, the higher the ALP, the higher bone transport state, and thus the higher the incidence of hypocalce-
mia after RFA. Our study found that the low calcium level of patients after ablation was closely and positively 
correlated with the preoperative serum ALP level. Higher ALP levels before ablation will cause more obvious 
postoperative hypocalcemia. It was similar with observations in recent decades, owing to the high values of ALP, 
patients may had higher risk for bone fractures and mortality due to hypocalcemia47,48. When the calcium level 
<1.8 mmol/L was defined as a standard of obvious low calcium, patients with ALP cutoff point at 566 mmol/L 
presented marked hypocalcemia with sensitivity of 95.0% and specificity of 94.6%. During follow-up 1 month 
after RFA, calcium levels before ablation were significantly lower in patients with ALP > 566 U/L than in patients 
with ALP < 566 U/L (1.94 ± 0.13 mmol/L vs. 2.16 ± 0.19 mmol/L) (P = 0.40). Our current study also found that 
the effects of single-session RFA and two-session RFA on hypocalcemia were different in patients depending on 
their ALP levels. For those patients with ALP of 566 mmol/L or higher, hypocalcemia was more pronounced in 
patients with single-session RFA compared with patients with two-sessions at day 1 after RFA (1.45 ± 0.25 mmol/L 
vs. 1.65 ± 0.20 mmol/L, P = 0.020). For those patients with ALP lower than 566 mmol/L, single-session group 
and two-session group calcium levels were similar (1.98 ± 0.10 mmol/L vs. 2.04 ± 0.30 mmol/L, P = 0.580). This 
finding implied that a single session of RFA in patients with high ALP was more likely to cause severe hypoc-
alcemia, while two sessions of RFA was more likely to cause mild hypocalcemia. The reason may be related to 
the step-by-step descent of PTH, with fractional ablation of the parathyroids in two sessions alleviating bone 
starvation.
Parathyroid glands are located in the area of the so-called cervical dangerous triangle. The local anatomy of 
this region has complex structures and the glands are closely adjacent to the recurrent laryngeal nerve. Thermal 
injury of the recurrent laryngeal nerve can cause voice change during the local coagulation of parathyroid glands. 
It is one of the most serious complications reported after RFA of both benign thyroid nodule and recurrent thy-
roid cancer, according to a study by Baek et al.49. Most patients with thermal damage of the nerve recover within 
2 to 3 months after RFA. In the current study, two patients (one in single-session RFA and another in two-session 
RFA) developed hoarseness after ablation, and they both recovered within 70 days. As described in our previous 
study, a fluid spacing ablation method and moving-shot technique with 1-mm spare margin of the glands can 
avoid thermal injury of carotid artery, esophagus, trachea and other adjacent structures, especially for recurrent 
laryngeal nerves30. There were no other severe complications during RFA or within the follow-up period in this 
study. Both our current and previous studies demonstrated that high resolution US-guided RFA of hyperplas-
tic parathyroid for treatment of patients with SHPT is safe and feasible by using either single- or two-session 
methods.
There were limitations of this study. First, the number of patients enrolled in our study was relatively small and 
more patients and long-term follow-up are needed to further study the efficacy and outcome. Second, CEUS was 
the only method used for monitoring the completion of the ablation. However, a 99mTc-sestamibi sequence may 
be needed to assess the result of ablation and efficacy of the treatment. Third, this study design cannot conclude 
how many parathyroid glands should be ablated at each session for optimal balance of ALP and hypocalcemia. 
At last, this study only followed up for 1 month period and long term follow-up study will conduct in the future.
In conclusion, this study showed that US-guided RFA of parathyroid hyperplasia is a safe and effective method 
for the treatment of secondary hyperparathyroidism. Hypocalcemia was likely to occur after RFA, with the degree 
of hypocalcemia related to pre-ablation serum ALP level. The preliminary results demonstrated hypocalcemia 
was relatively mild in patients with two-session of RFA, especially for patients with baseline ALP > 566 mmol/L. 
Although single-session RFA of parathyroid hyperplasia was more cost-effective and required a shorter hospital 
stay, patients with ALP ≥ 566 mmol/L should have two-session RFA in order to avoid severe hypocalcemia after 
ablation. Patients with ALP < 566 mmol/L could choose either single- or two-session RFA, depending on their 
condition and on affordability.
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